Ruxolitinib (Novartis) is another approved inhibitor for the treatment of myelofibrosis, which targets both JAK1 and JAK2 and is currently being used in a number of clinical studies (phase I, II, and III) in solid tumors including BC [173]. The gene discussed is JAK1; the disease is myelofibrosis.